Latest News & Features
Big Pharma
Patentees should ensure their applications meet the plausibility standard right from the start, says Iain Armstrong of HGF, who investigates one of the
developing challenges facing patentability in the life sciences field. 24 October 2017
Americas
If biotech companies in Brazil understand that they can use both plant variety and patent protection in certain cases, their ability to innovate may improve, says Gabriel Di Blasi of Di Blasi, Parente & Associados. 24 October 2017
Big Pharma
If the UK government changes the rules for clinical trials after Brexit, the regimes in the UK and the EU will diverge and possibly make trials more complex and costly, as Rachel Bradley of Penningtons Manches reports. 10 October 2017
article
Canada has a robust and reliable framework for resolving IP disputes, and it shouldn’t be ignored by litigants, say Ron Dimock, Sangeetha Punniyamoorthy and Nikolas Purcell of DLA Piper. 2 October 2017
Americas
With discussions underway to create a CRISPR patent pool, Kevin O’Connor of Neal, Gerber & Eisenberg discusses the three main perspectives when considering the main benefits of such a move. 15 September 2017
Americas
Inter partes reviews filed by generic drug companies have a higher institution rate but lower invalidation rate compared to other IPRs, say Wenhua Yu, Stephen Maebius and Tianran Yan of Foley & Lardner. 30 August 2017
Americas
The patent system in the US and the EU is not rewarding complex research into treatments for a host of prevalent diseases and conditions, and reforms are going in the wrong direction, says Erika Lietzan of the University of Missouri School of Law. 12 July 2017
Big Pharma
Precision medicine has come a long way since the completion of the Human Genome Project in 2003, but how have IP regimes developed in this area, asks Sheena Linehan of Potter Clarkson. 12 July 2017
article
With the two-year Brexit negotiations underway, life sciences companies and their lawyers will be watching closely to see how their businesses and IP will be affected. LSIPR reports with views from the UK, France and Germany. 10 July 2017
Sectors
With legal developments in the CRISPR field ramping up this year, LSIPR examines the current international landscape and the options for parties interested in using the gene-editing technology. 9 July 2017